Royalty Pharma Plc (RPRX) revenue breakdown
By product, Income from financial royalty assets is the largest at 95% of fiscal 2025 revenue, growing 6% a year over 7 years.
Revenue by product
Fiscal years, as Royalty Pharma Plc reports them in its 10-K filings; fiscal 2025 total $2.4B.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Income from financial royalty assets | $1.5B | $1.6B | $2.0B | $2.1B | $2.1B | $2.2B | $2.1B | $2.3B | 95% |
| Other royalty income and revenues | $136M | $20M | $19M | $53M | $112M | $157M | $114M | $117M | 5% |
| Revenue from intangible royalty assets | $134M | $146M | $143M | $171M | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RPRX.
Open RPRX in InvestinglyQuestions
Where does Royalty Pharma Plc make its money?
In fiscal 2025, by product: Income from financial royalty assets $2.3B, Other royalty income and revenues $117M.
From Royalty Pharma Plc's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.